Story Highlight
– Ramipril may cause rare angioedema reactions in users.
– Reaction can lead to serious swelling and breathing issues.
– Awareness of delayed reactions is essential for patients.
– ACE inhibitor cough affects one in ten users commonly.
– Ongoing drug shortages raise patient safety concerns significantly.
Full Story
A recent advisory issued by the Medicines and Healthcare Products Regulatory Agency (MHRA) has brought to light a significant health warning for individuals prescribed ACE inhibitors, particularly ramipril, a drug commonly utilised in the management of hypertension. Dr Mark Porter, a prominent general practitioner and familiar face from various television health programmes, emphasised the importance of this alert, underscoring the potential serious side effect known as angioedema, which can lead to swelling in various parts of the body including the face, lips, tongue, and throat.
According to Dr Porter, the prevalence of these medications in the UK is substantial, with countless patients relying on them not only for high blood pressure but also for other health conditions. “The side-effect is something every person taking an ACE inhibitor, and every doctor prescribing it, should acknowledge, hence this latest MHRA safety update,” he stated. The agency noted that angioedema, although relatively rare, may affect an estimated 1 in 140 to 1 in 1,000 individuals taking drugs like ramipril.
Angioedema can manifest unexpectedly and is characterised by swelling that may occur after patients have been on ACE inhibitors for an extended period without prior complications. Severe reactions may hinder breathing and swallowing, posing a life-threatening risk. Those most susceptible include women, older adults over 65, smokers, and individuals of Black or African-Caribbean descent.
Dr Porter specifically highlighted two crucial messages from the MHRA alert for both patients and healthcare professionals. The first emphasises the potential for delayed reactions, which might arise weeks or even months following the initiation of treatment. Such reactions are distinct from typical allergic responses, which usually prompt immediate medical intervention. “Conventional therapies, including adrenaline injections typically used for anaphylaxis, may not be suitable in these cases,” he noted.
The second critical point concerns the awareness that angioedema, while infrequent, can occur at any time during the course of treatment, and patients should be aware of symptoms that necessitate urgent medical care. This includes immediate medical assistance if swelling or breathing difficulties arise. Dr Porter urged those taking ACE inhibitors to inform their healthcare providers of any previous episodes of angioedema and to be cognisant that alternative causes for swelling may be considered, which could still warrant the use of ACE inhibitors.
Reflecting on his own clinical experiences, Dr Porter acknowledged that he has encountered patients who developed angioedema. “I have had patients of mine develop angioedema on these drugs but, despite prescribing it to thousands over the past 40 years, I have never seen a life-threatening reaction,” he remarked. He reiterated that while the warning is significant, it does not signify a widespread problem, but rather highlights an issue that requires increased awareness.
In addition to angioedema, Dr Porter brought attention to another common side effect associated with ACE inhibitors known as the ACE-inhibitor cough. This condition is reported to affect approximately one in ten patients on these medications. The cough is typically dry and can be persistent, often leading to frustration rather than severe impairment. “The precise cause of this side effect is still being debated, but the medications may heighten the sensitivity of the cough reflex, resulting in frequent, unnecessary coughing,” he explained.
Dr Porter added that this cough can develop over days, weeks, or even months after the initiation of treatment, highlighting that sometimes it may only become apparent following a minor illness such as a chest infection. He cautioned that in such cases, both patients and physicians may mistakenly attribute the cough to other medical conditions, obscuring the link to the medication. Fortunately, he pointed out that recognising this side effect typically allows for straightforward resolution via a switch to another class of medications known as sartans.
It’s worth noting that patients prescribed ACE inhibitors should exercise caution when considering non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or naproxen, which could potentially exacerbate kidney issues in some individuals. Dr Porter advised against using these over-the-counter pain relievers without consulting a healthcare provider, suggesting that paracetamol may pose fewer risks in this context.
Amid these health warnings, the UK is facing significant challenges regarding medication shortages, particularly for commonly prescribed treatments. The National Pharmacy Association (NPA) has reported that shortages are jeopardising patient safety, highlighting difficulties in accessing essential medications, including blood pressure drugs and pain management options. The Royal College of GPs advocates for expanded pharmacy roles in adjusting prescriptions when certain medicines are unavailable to ensure patient safety.
Among the medicines affected by these shortages is ramipril, as well as co-codamol and specific low-dose aspirin formulations. Additionally, there is an ongoing scarcity of Creon, a critical medication for patients suffering from conditions like cystic fibrosis and pancreatic cancer, which has led to difficult decisions regarding medication rationing among those dependent on it. The European Medicines Agency has noted that production limitations combined with high demand may extend these shortages well into 2027.
As patients navigate these challenges, the current guidance surrounding ACE inhibitors and potential side effects remains crucial. Adapting treatment as necessary while maintaining open communication with healthcare professionals will be key to ensuring ongoing health and safety in the face of these evolving dynamics.
Our Thoughts
To prevent the adverse reactions associated with ACE inhibitors like ramipril, improved patient education and robust monitoring practices are essential. Healthcare professionals must ensure patients are fully informed about the potential side effects, such as angioedema, and the importance of seeking immediate medical attention if symptoms arise. The Medicines and Healthcare Products Regulatory Agency (MHRA) updates should be disseminated effectively to both prescribers and patients to elevate awareness.
Key regulations breached could include the Health and Safety at Work Act 1974, which mandates that employers ensure the health and safety of their employees and others affected by their work, and the Management of Health and Safety at Work Regulations 1999, requiring risk assessments and implementing appropriate control measures.
Similar incidents could be curtailed by introducing compulsory annual reviews of medications and their side effects, along with protocols for reporting and addressing adverse events promptly. Additionally, addressing medication shortages proactively to prevent patients from being switched to alternatives without proper supervision can further safeguard against risks associated with untreated conditions.
